Critical Review: Opko Health (OPK) and Juniper Pharmaceuticals (JNP)
Opko Health (NASDAQ: OPK) and Juniper Pharmaceuticals (NASDAQ:JNP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.
Earnings & Valuation
This table compares Opko Health and Juniper Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Opko Health||$1.22 billion||2.20||-$25.08 million||($0.22)||-21.86|
|Juniper Pharmaceuticals||$54.57 million||0.94||$5.95 million||$0.59||8.05|
This table compares Opko Health and Juniper Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
22.9% of Opko Health shares are owned by institutional investors. Comparatively, 36.4% of Juniper Pharmaceuticals shares are owned by institutional investors. 40.2% of Opko Health shares are owned by company insiders. Comparatively, 7.2% of Juniper Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Opko Health has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Juniper Pharmaceuticals has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500.
This is a breakdown of recent ratings for Opko Health and Juniper Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Opko Health currently has a consensus target price of $14.81, indicating a potential upside of 207.95%. Juniper Pharmaceuticals has a consensus target price of $23.00, indicating a potential upside of 384.21%. Given Juniper Pharmaceuticals’ higher probable upside, analysts clearly believe Juniper Pharmaceuticals is more favorable than Opko Health.
Juniper Pharmaceuticals beats Opko Health on 7 of the 13 factors compared between the two stocks.
About Opko Health
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.